Researchers at the Batista Lab have identified a gap in current malaria vaccines, which only target one region of the parasite. Adding short peptides to these regions can broaden the immune response and improve protection.
A study from the Ragon Institute reveals how a live bacterial therapy works to prevent recurrent bacterial vaginosis (BV) and why it works better for some women than others. The therapy, LACTIN-V, was found to successfully colonize the beneficial bacterium Lactobacillus crispatus in 30% of women, leading to improved vaginal health.
Researchers at Ragon Institute discovered that antibodies produced in germinal centers act as a 'brake' on selection, redirecting the immune system toward broader protection. Stronger-binding B cells suppress weaker ones targeting the same site, establishing a localized feedback loop.
Researchers identified specific antibody features that limit Mtb growth, revealing critical insights into antibody-immune cell interactions. The study lays groundwork for potential antibody-based therapies or vaccines against tuberculosis, an urgently needed treatment for the deadly infectious disease.
Researchers developed MUNIS, a deep learning tool that predicts CD8+ T cell epitopes with high accuracy, potentially accelerating vaccine development. The tool was validated using experimental data from influenza, HIV, and EBV, demonstrating its potential to streamline vaccine design.
Researchers at Ragon Institute of MGH, MIT and Harvard have developed a comprehensive platform for HIV vaccine research using the mRNA-LNP system. The platform has shown promising results in preclinically validating next-step boost immunogens and providing new insights into the basic biology of antibody responses.
Researchers have found that antibody sequences contain an unusual number of codons without corresponding tRNAs, which can be bridged by the inosine wobble modification. This modification allows for more efficient production of antibodies, with implications for vaccine efficacy and rationally designed vaccines.
Researchers found that vaccinated B cell-deficient individuals have a robust T cell response to SARS-CoV-2, despite lack of anti-spike antibodies, resulting in markedly reduced rates of hospitalization and severe COVID-19. This study provides reassuring evidence for immunocompromised patients to get vaccinated.